All In Biotech

Drug Trial Radar · NCT04225208

Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD4205 in Healthy Adult Male Volunteers

A Phase I, Single-centre, Non-Randomised, Open-label, Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD4205 in Healthy Adult Male Subjects

Last checked: Nov 19, 2026Latest source record: Aug 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Jan 6, 2020

Primary completion

Mar 2, 2020

Study completion Mar 2, 2020

Sponsor

Lead sponsor
Dizal PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jan 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase I, open label, healthy volunteers, ADME study with single oral administration of \[14C\]-AZD4205.

Conditions

  • Healthy Volunteers

Interventions

  • [14C]-AZD4205, single 50 mg oral dose administrated on day 1Drug

    Each subject will receive 50 mg AZD4205 oral solution (free base equivalent) containing a nominal dose of 15 µCi \[14C\]- radiolabelled AZD4205 as a single administration .

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of radioactive dose recovered in urine and faeces and total percentageTime frame: Up to 57 days
  2. Provide samples for subsequent studiesTime frame: Up to 57 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pharmaron CPC

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.